Home

MICHAEL MORNEAU

CIK 1517780 · VP, Finance and Administration · last filed 2021-01-19

MICHAEL MORNEAU is a VP, Finance and Administration who has filed 23 SEC Form 4 insider transactions across 3 companies since 2012. The most recent filing shows the insider had shares withheld for taxes covering $11.3K of VKTXW on Jan 19, 2021. Across all open-market trades the lifetime net is −$549.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.0M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.99M

Companies

3

Total Filings

23

Lifetime Open-Market Net

-$549.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Viking Therapeutics, Inc. (VKTXW) Delisted VP, Finance and Administration 116,062 $4.60 $533.9K -$199.3K 15 2021-01-19
VKTX Chief Financial Officer 67,000 $29.65 $1.99M $0 3 2016-03-15
Trius Therapeutics Inc (TSRX) Delisted VP Finance & CAO 32,545 — — -$350.0K 4 2013-07-12

Recent Filings

23 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-01-19 Viking Therapeutics, Inc. (VKTXW) Delisted Tax (F) −1,685 -$11.3K EDGAR
2021-01-06 Viking Therapeutics, Inc. (VKTXW) Delisted Mixed +18,595 -$15.9K EDGAR
2020-09-16 Viking Therapeutics, Inc. (VKTXW) Delisted Mixed +2,943 -$9.7K EDGAR
2020-04-03 Viking Therapeutics, Inc. (VKTXW) Delisted Grant (A) — $0 EDGAR
2020-01-21 Viking Therapeutics, Inc. (VKTXW) Delisted Tax (F) −2,044 -$14.7K EDGAR
2020-01-03 Viking Therapeutics, Inc. (VKTXW) Delisted Grant (A) — $0 EDGAR
2019-10-31 Viking Therapeutics, Inc. (VKTXW) Delisted Grant (A) — $0 EDGAR
2019-08-02 Viking Therapeutics, Inc. (VKTXW) Delisted Grant (A) — $0 EDGAR
2019-01-22 Viking Therapeutics, Inc. (VKTXW) Delisted Tax (F) −2,044 -$17.9K EDGAR
2019-01-03 Viking Therapeutics, Inc. (VKTXW) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 23
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.